Stockscreener 앱 받기
136.64
1.44%
-2.00
시간 외 거래:
136.64
전일 마감가:
$138.64
열려 있는:
$138.36
하루 거래량:
548.76K
Relative Volume:
0.80
시가총액:
$8.79B
수익:
$74.06M
순이익/손실:
$-114.71M
주가수익비율:
-75.75
EPS:
-1.8039
순현금흐름:
$-117.90M
1주 성능:
+0.39%
1개월 성능:
+11.47%
6개월 성능:
+67.04%
1년 성능:
+153.69%
1일 변동 폭
$131.69
$138.37
1주일 범위
$130.63
$139.92
52주 변동 폭
$50.48
$143.29
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
136.64 | 8.72B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Protagonist Therapeutics Inc - TradingKey
Protagonist Therapeutics Market Sentiment - Benzinga España
Protagonist Therapeutics Inc (PTGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protagonist Therapeutics Inc (PTGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PTGX|Protagonist Therapeutics Inc|Price:136.110|Chg%:+0.680 - TradingKey
Protagonist Therapeutics Inc (PTGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Protagonist Therapeutics, Inc. Revenue Breakdown – NASDAQ:PTGX - TradingView
TradingKey - TradingKey
Protagonist Therapeutics Inc (PTGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
PTGX Pulls Back: Protagonist Therapeutics Holds Above Support After Modest DeclineDealer Gamma - dars.gov.et
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
PROTAGONIST THERAPEUTICS INC : JEFFERIES RAISES TARGET PRICE TO $172 FROM $121 - Bitget
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup - ChartMill
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $155 - Moomoo
Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com - Investing.com Australia
Liquidity Mapping Around (PTGX) Price Events - Stock Traders Daily
PROTAGONIST THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $155 FROM $100 - Bitget
Protagonist Therapeutics stock hits all-time high at 141.79 USD - Investing.com
Protagonist Therapeutics (PTGX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
Protagonist Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open - Sahm
Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Citizens raises Protagonist Therapeutics price target on Icotyde uptake By Investing.com - Investing.com Canada
Citizens JMP Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Three New Hires Receive Protagonist Options and RSUs Under Inducement Plan - Stock Titan
Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight - AlphaStreet
Protagonist Therapeutics Is Maintained at Overweight by Barclays - Moomoo
PTGX Maintained by Barclays -- Price Target Raised to $151 - GuruFocus
Barclays Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Best Momentum Stocks to Buy for July 13th - Yahoo Finance Singapore
Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Protagonist Therapeutics (PTGX) AGM 2026 Summary - Quartr
Protagonist Therapeutics (PTGX) Investor Update Summary - Quartr
Protagonist Therapeutics Inc. (PTGX) Q1 2026 Earnings: Surprise Profitability Defies Estimates, Yet Shares SlideEPS Consistency Score - dars.gov.et
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review - Yahoo Finance
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued - Yahoo Finance
New Strong Buy Stocks for July 9th - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest - simplywall.st
Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review FocusHas The Bull Case Changed? - Yahoo Finance
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains? - Yahoo Finance
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX) - The Globe and Mail
PTGX climbs as target hike adds to late-stage pipeline optimism - Quiver Quantitative
PTGX Stock Grinds Higher As Pipeline Catalysts Build - StocksToTrade
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com India
Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies - ad-hoc-news.de
Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally - AlphaStreet
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Protagonist Therapeutics Inc 주식 (PTGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Jun 23 '26 |
Sale |
117.94 |
9,000 |
1,061,460 |
7,825 |
2.44%
0.02%
자본화:
|
볼륨(24시간):